48 unknown. 48 Phase 3, 9 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 48 | Unknown 48 |
| Phase 2 | 9 | Unknown 9 |
Follow Hemostatic Disorders: new trials by email Literature Review of Hemostatic Disorders trials Research Report on Hemostatic Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of the Efficacy and Safety of Monotherapy With BCD-264 and Darzalex in Subjects With Relapsed and Refractory Multiple Myeloma BCD-264, Darzalex - Multiple Myeloma | Phase 3 | Unknown | Biocad | 252 | 2023-12-21 | 2024-03-06 |
| Lapelga vs Gastrofil Grastofil®, Lapelga - Multiple Myeloma, Lymphoma | Phase 3 | Unknown | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 74 | 2023-11-01 | 2023-11-03 |
| CURATE.AI Optimized Modulation for Multiple Myeloma Bortezomib, Cyclophosphamide, Dexamethasone - Multiple Myeloma | Phase 2 / Phase 3 | Unknown | National University Hospital, Singapore | 20 | 2023-09-10 | 2023-09-06 |
| The Efficacy and Safety of Colchicine Combined With Conventional Therapy in Multiple Myeloma Patients Colchicine, Lenalidomide - Multiple Myeloma | Phase 3 | Unknown | Affiliated Hospital of Nantong University | 30 | 2022-03-30 | 2023-04-07 |
| Observation of the Efficacy of BAd Regimen in the Treatment of Relapsed and Refractory Multiple Myeloma Bendamustine - Bendamustine, Multiple Myeloma | Phase 3 | Unknown | Liao Aijun | 10 | 2021-06-01 | 2021-08-16 |
| A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma Pomalidomide, Dexamethasone - Multiple Myeloma, Recurrent or Refractory | Phase 3 | Unknown | Qilu Pharmaceutical Co., Ltd. | 85 | 2021-01-04 | 2022-02-11 |
| Steroids and Unfractionated Heparin in Critically Ill Patients With Pneumonia From COVID-19 Infection Enoxaparin, Methylprednisolone, unfractionated heparin - Covid19, SARS-CoV Infection | Phase 3 | Unknown | Massimo Girardis | 210 | 2020-11-25 | 2021-05-06 |
| Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With Newly Diagnosed Multiple Myeloma R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - reactive arm, R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - adaptive arm, R2: Lenalidomide plus placebo maintenance - Multiple Myeloma | Phase 3 | Unknown | University of Leeds | 740 | 2020-08-04 | 2021-06-15 |
| High Versus Low LMWH Dosages in Hospitalized Patients With Severe COVID-19 Pneumonia and Coagulopathy Enoxaparin - COVID, Pneumonia, Viral | Phase 3 | Unknown | Azienda Ospedaliero-Universitaria di Modena | 300 | 2020-06-01 | 2020-05-29 |
| Efficacy of Colchicine to Prevent Skin Relapses in Adult's IgA Vasculitis Colchicine - IgA Vasculitis | Phase 3 | Unknown | Assistance Publique - Hôpitaux de Paris | 264 | 2019-11-12 | 2021-10-04 |
| Rivaroxaban or Aspirin As Thromboprophylaxis in Multiple Myeloma Rivaroxaban, ASA - Multiple Myeloma in Relapse, Multiple Myeloma Progression | Phase 2 / Phase 3 | Unknown | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 57 | 2019-01-17 | 2024-02-29 |
| Daratumumab Intensified Treatment to Eligible MM New Patients CTD-Dara Induction, Follow by Dara Consolidation Cyclo Thal Dex Daratumumab - Multiple Myeloma Stage I | Phase 3 | Unknown | Grupo de Estudos Multicentricos em Onco-Hematologia | 20 | 2018-11-20 | 2019-01-03 |
| Sclerotherapy With Polidocanol Foam In The Treatment Of Hemorrhoidal Disease In Patients With Bleeding Disorders Polidocanol foam sclerotherapy - Hemorrhoids, Bleeding Disorder | Phase 2 / Phase 3 | Unknown | Universidade do Porto | 150 | 2018-08-01 | 2020-08-19 |
| Edoxaban for the Treatment of Coagulopathy in Patients With Active Cancer and Acute Ischemic Stroke: a Pilot Study. (ENCHASE Study) Edoxaban, Enoxaparin - Correction of Cancer-related Coagulopathy With Novel Oral Anticoagulant (Edoxaban) | Phase 2 / Phase 3 | Unknown | Samsung Medical Center | 40 | 2018-06-15 | 2018-06-26 |
| Mel vs BUCY+VP-16 Conditioning Regimen for MM Undergoing Auto-HSCT Busulfan (BU), Cyclophosphamide (CY), Etoposide (VP-16) - Autologous Hematopoietic Stem Cell Transplantation, Conditioning | Phase 2 / Phase 3 | Unknown | Nanfang Hospital, Southern Medical University | 122 | 2018-01-02 | 2020-02-25 |
| Study of BiRd Regimen Combined With BCMA CAR T-cell Therapy in Newly Diagnosed Multiple Myeloma (MM) Patients clarithromycin, lenalidomide, dexamethasone and autologous BCMA-directed CAR T-cells - Multiple Myeloma | Phase 3 | Unknown | The First Affiliated Hospital of Soochow University | 20 | 2017-10-19 | 2021-10-25 |
| Treatment of Nasal Staphylococcus Aureus Colonization in Patients With HHT Mupirocin, Placebo - Hereditary Hemorrhagic Telangiectasia, Epistaxis | Phase 3 | Unknown | Hospital Italiano de Buenos Aires | 40 | 2017-06-01 | 2016-11-15 |
| Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers Ibrutinib - Chronic Lymphocytic Leukemia, Indolent B-cell Lymphomas | Phase 3 | Unknown | The University of Hong Kong | 62 | 2016-11-01 | 2018-04-12 |
| Efficacy and Safety of Pomalidomide in Combination With Low-dose Dexamethasone in Chinese Patients With Relapsed and Refractory Multiple Myeloma Pomalidomide, Dexamethasone - Multiple Myeloma | Phase 3 | Unknown | Jiangsu Simcere Pharmaceutical Co., Ltd. | 73 | 2016-09-01 | 2016-11-02 |
| GEM-CLARIDEX: Ld vs BiRd Clarithromycin, Lenalidomide, Dexamethasone - Multiple Myeloma | Phase 3 | Unknown | PETHEMA Foundation | 286 | 2015-09-01 | 2022-02-01 |
Showing 20 of 48. Sign in to see all of them.
Multiple Myeloma (38) · Neoplasms, Plasma Cell (9) · Leukemia, Lymphocytic, Chronic, B-Cell (6) · Lymphoma (6) · Lymphoma, Follicular (6) · Lymphoma, B-Cell, Marginal Zone (5) · Lymphoma, Mantle-Cell (5) · Lymphoma, Non-Hodgkin (5) · Burkitt Lymphoma (4) · Hodgkin Disease (4) · Leukemia (4) · Lymphoma, Large B-Cell, Diffuse (4) · Lymphoma, Large-Cell, Immunoblastic (4) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (4)
Cardiovascular Diseases (48) · Hemic and Lymphatic Diseases (48) · Hemorrhagic Disorders (48) · Vascular Diseases (48) · Hematologic Diseases (47) · Immune System Diseases (42) · Blood Protein Disorders (41) · Immunoproliferative Disorders (41) · Lymphoproliferative Disorders (41) · Neoplasms by Histologic Type (41) · Paraproteinemias (41) · Neoplasms (40) · Neoplasms, Plasma Cell (32) · Pathological Conditions, Signs and Symptoms (14)
Dexamethasone (15) · Cyclophosphamide (13) · Melphalan (9) · Lenalidomide (7) · Thalidomide (6) · Bortezomib (5) · Doxorubicin (5) · Prednisone (4) · Clarithromycin (3) · Enoxaparin (3) · Filgrastim (3) · Interferon-alpha (3) · Busulfan (2) · Carmustine (2) · Colchicine (2)
Grupo de Estudos Multicentricos em Onco-Hematologia (2) · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (2) · Medical Research Council (2) · University of Leeds (2) · Affiliated Hospital of Nantong University (1) · Assistance Publique - Hôpitaux de Paris (1) · Azienda Ospedaliera San Giovanni Battista (1) · Azienda Ospedaliero-Universitaria di Modena (1) · Biocad (1) · Charite University, Berlin, Germany (1) · Clatterbridge Centre for Oncology (1) · Commissie Voor Klinisch Toegepast Onderzoek (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Heidelberg University (1) · Hospital Italiano de Buenos Aires (1)
United Kingdom (10) · China (8) · Germany (5) · Italy (5) · France (4) · Belgium (3) · Brazil (2) · Israel (2) · Netherlands (2) · Russia (2) · Argentina (1) · Austria (1) · Canada (1) · Hong Kong (1) · Iran (1)
Aili He, MD, PhD (1) · Ardeshir Ghavamzadeh, MD (1) · Baijun Fang, MD, PhD (1) · Barry J.A. Laird, MD (1) · Benedetto Bruno, MD, PhD (1) · Bertrand Coiffier, MD (1) · Binghua Wang, MD, PhD (1) · Congmeng Lin, MD, PhD (1) · Da Gao, MD, PhD (1) · Diana Samson, MD (1) · Eliezer Rachmilewitz, MD (1) · Ernest Marshall, MD (1) · Fernando Dimeo, MD (1) · Gerlinde Egerer, MD (1)
PMID 35244208, PMID 11137554, PMID 11231246, PMID 12510709, PMID 15131807, PMID 15189396, PMID 15711856, PMID 15842354, PMID 16103468, PMID 16427380, PMID 16475046, PMID 17360989, PMID 17859247, PMID 18094721, PMID 18166796, PMID 18239868, PMID 18276714, PMID 19095121, PMID 19166855, PMID 19387663, PMID 19880501, PMID 19952380, PMID 20006130, PMID 20011381, PMID 20109630, PMID 20637084, PMID 21146205, PMID 21410373, PMID 21849487, PMID 21872920, PMID 21932016, PMID 22058209, PMID 22409262, PMID 22413048, PMID 22442350, PMID 22498745, PMID 2295392, PMID 23089912, PMID 23298856, PMID 23470618, PMID 23721099, PMID 23775099, PMID 23897961, PMID 23903204, PMID 24239254, PMID 24749117, PMID 24948586, PMID 25225424, PMID 25433198, PMID 25439696
2005 (1), 2009 (1), 2015 (1), 2018 (1)